A pharma giant is moving past one patent cliff — but another is already looming
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Marchés
A pharma giant is moving past one patent cliff — but another is already looming
TradeNews BD, note actions-FX-crypto (2026-10-30): Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks. Source primaire : original chez CNBC Top News (cnbc.com).